


Receipt



TRANSMITTAL LETTER			Case No. 10716/15
Serial No. 09/703,350	Filing Date October 31, 2000	Examiner	Group Art Unit 1644
Inventor(s) Mehraban et al.			
Title of Invention DIFFERENTIALLY EXPRESSED GENES INVOLVED IN ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING THE SAME			

**FILE COPY**

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is Transmittal sheet (in duplicate); Correction of Filing Receipt and return-receipt postcard.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a \_\_\_\_\_ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

**RECEIVED**

**SEP 21 2001**

**TECH CENTER 1600,2900**

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity	
Rate	Add'l Fee
x \$9=	
x 40=	
+\$135=	
Total add'l fee	\$

or

Other Than Small Entity	
Rate	Add'l Fee
x \$18=	
x \$80=	
+\$270=	
Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$\_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Paul E. Rauch  
Registration No. 38,591  
Attorney for Applicant

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, ILLINOIS 60610  
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on June 8, 2001.

Date: June 8, 2001

Signature:



I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, D.C. 20231

6/8/01

on

Date of Deposit

Paul Rauch

Name of applicant, assignee or  
Registered Representative

[Signature]

Signature

6/8/01

Date of Signature

RECEIVED

SEP 21 2001

TECH CENTER 1600/2900

Our Case No. 10716/15

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Mehraban et al.

Serial No. 09/703,350

Filing Date: 10/31/2000

For DIFFERENTIALLY EXPRESSED  
GENES INVOLVED IN  
ANGIOGENESIS, THE  
POLYPEPTIDES ENCODED  
THEREBY, AND METHODS OF  
USING THE SAME

Examiner

Group Art Unit No. 1644

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Commissioner for Patents  
Washington, D.C. 20231

Attention: Application Processing Division  
Customer Correction Branch

Sir:

Applicants request the issuance of a corrected filing receipt (copy enclosed)  
for the above-referenced patent application, and in support of this request  
respectfully states:



U.S. Serial No. 09/703,350  
Filed: 10/13/2000  
Page 1 of 2

Under **ATTY. DOCKET NO.**, please delete "15966-590 (CURA-90)" and  
replace with -10716/15 (CURA-90/P1891R1)—

Under **CONTINUING DATA AS CLAIMED BY APPLICANT**, the data are  
missing. Please insert:

—60/162,669 filed 11/01/99—

--60/196,802 filed 04/13/00—

Under **Title**, please delete "angiogenesis" and replace with -angiogenesis--

The Commissioner is hereby authorized to charge any fees required to  
Deposit Account No. 23-1925.

Respectfully submitted,

Paul E. Rauch, Ph.D.  
Registration No. 38,591  
Attorney for Applicant

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, ILLINOIS 60610  
(312) 321-4200



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov


FILE COPY



Bib Data Sheet

CONFIRMATION NO. 3065

<b>SERIAL NUMBER</b> 09/703,350	<b>FILING DATE</b> 10/31/2000 <b>RULE</b>	<b>CLASS</b> 530	<b>GROUP ART UNIT</b> 1644	<b>ATTORNEY DOCKET NO.</b> 10716-15 (CURA-90/P1891R1)	
<b>APPLICANTS</b> Fuad Mehraban, Trumbull, CT; Mary Gerritsen, San Mateo, CA; Luca Rastelli, Guilford, CT;					
<b>** CONTINUING DATA *****</b> THIS APPLN CLAIMS BENEFIT OF 60/162,699 11/01/1999 AND CLAIMS BENEFIT OF 60/196,802 04/13/2000					
<b>** FOREIGN APPLICATIONS *****</b>					
<b>IF REQUIRED, FOREIGN FILING LICENSE GRANTED</b> <b>** 02/22/2001</b>					
Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance		<b>STATE OR COUNTRY</b> CT	<b>SHEETS DRAWING</b> 19	<b>TOTAL CLAIMS</b> 68	<b>INDEPENDENT CLAIMS</b> 15
Verified and Acknowledged Examiner's Signature _____ Initials _____					
<b>ADDRESS</b> Paul E. Rauch, Ph. D. BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610					
<b>TITLE</b> Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same					
<b>FILING FEE RECEIVED</b> 2664	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.govRECEIVED  
Page 1 of 3  
SEP 21 2001  
TECH CENTER 1600/2900

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/703,350	10/31/2000	1644	2534	15968-590 (CURA-90) 10716/15 (CURA-90/P1891R1)	19	68	15

FILING RECEIPT




\*OC000000005790494\*

Ivor R Elrifi Esq  
Mintz Levin Cohn Ferris Glovsky and Popeo PC  
One Financial Center  
Boston, MA 02111

Date Mailed: 02/22/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Fuad Mehraban, New Haven, CT ;  
Mary Gerritsen, San Mateo, CA ;  
Luca Rastelli, Guilford, CT ;Continuing Data as Claimed by Applicant  
60/162,669 filed 11/01/99  
60/196,802 filed 4/13/00  
Foreign Applications

If Required, Foreign Filing License Granted 02/22/2001

## Title

Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby,  
and methods of using the same

angiogenesis

## Preliminary Class

530

Data entry by : DILLON, LAWANDA

Team : OIPE

FEB 28 2001  
Date: 02/22/2001

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to: